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Metalloporphyrins not only participate in a wide range of essential biochemical 
reactions, but have also recently received attention as therapeutic agents.  He- 
matoporphyrins, which produce  photodynamic destructive effects on cells are 
under  investigation as  antineoplastic agents (1,  2).  Tin-protoporphyrin  IX, a 
metal  substitution  of heme,  potently  inhibits  heme-oxygenase  and  has  been 
suggested  in  the  treatment  of hyperbilirubinemia  (3-5).  And,  because  heine 
(ferriprotoporphrin  IX)  suppresses  b-aminolevulinic  acid  synthetase,  hematin 
(ferriprotoporphyrin IX hydroxide) is being used to prevent or abate the painful 
crises of patients wth acute intermittent porphyria (ALP)  1 (6-8). 
Although  the  overall  toxicity of hematin  infusions appears  to  be  minimal, 
profound effects on the routine tests of blood coagulation have recently been 
reported  (9-1 1).  Decreased  platelet  count and  fibrinogen concentration,  and 
prolonged thrombin  (TT),  prothrombin  (PT),  and activated partial  thrombo- 
plastin (APTT) times are reported in a picture that mimicks diffuse intravascular 
coagulation. This study focuses on the mechanism of the fluid phase coagulation 
defect produced  by  hematin.  The  results  indicate  that,  in  vitro  and in  vivo, 
hematin is oxidatively degraded  or metabolized to an anticoagulant, and  that 
hematin  itself is  not  responsible  for  the  prolongation  of clotting  times.  The 
results also suggest that this anticoagulant is a  single derivative of hematin that 
binds to clotting proteins to reversibly inhibit their function, and which involves 
iron in its mechanism of action. 
Materials and Methods 
Hematin.  Hematin was prepared by two methods. (a) Heroin, assayed 101% purity by 
pyridine hemochromogen, (Porphyrin Products, Logan, UT) was dissolved in 1 N NaOH 
(0.2 ml for each milliliter of hematin solution), then 0.8 ml of potassium phosphate buffer 
(pH  7.5)  was  added. The final pH,  7.5,  was adjusted with  1 N  HCI.  (b)  Hemin was 
dissolved in 1 N sodium carbonate (pH 12). The final pH of 7.5 was obtained by adding 
1 N  HC1. Tin-protoporphyrin IX, and protoporphyrin IX (Porphyrin Products) were 
prepared as per preparation (a) for hematin. The final concentration for all porphyrin 
solutions was 10 mg/ml. Hematin concentrations were confirmed by the pyridine hemo- 
This work was supported, in part, by a Special Emphasis Research Career Award from the U.S. 
Public Health Service AM-0059003, by U.S.P.H.S. grants ES~01055, CA29502 (CNRU), RR 00102 
(GCRC), and by gifts from the Renfield Foundation  and the Dyson  Foundations.  Address  correspond- 
ence to R. Jones, The Rockefeller  University, 1230 York Ave., New York, NY 10021. 
L Abbreviations  used  in  this paper:  AIP, acute intermittent porphyria; APTT, activated partial 
thromboplastin time; BHT, butylated hydroxytoluene; HDA, hematin-derived anticoagulant; PT, 
prothrombin time; TBAH, tetrabutylammonium hydroxide; TT, thrombin time. 
7 24  J. ExP. MEt). © The Rockefeller  University  Press - 0022-1007/86/03/0724/16  $1.00 
Volume 163  March 1986  724-739 JONES  725 
chromogen assay. (t 2) Unless otherwise indicated, all other reagents were of the highest 
grade  available  from  Sigma  Chemical  Co.,  St.  Louis,  MO,  or  Fisher  Scientific  Co., 
Pittsburgh, PA. 
Clotting Assays.  Clotting times were measured in duplicate with an automated optical 
coagulation recorder (Biodata Corp., Horsham, PA). Clotting times were also measured 
in the dark with a  mechanical clot detection device (Fibrometer, Becton Dickinson and 
Co., Sunnyvale, CA). Clotting times were measured using commercial reagents. PT and 
APTT were measured with Simplastin, lot 4D831; and Automated PTT, lots 4M610 and 
4M842 (General Diagnostics, Morris Plains, NJ).  TT was measured with Bovine Topical 
Thrombin  (Parke-Davis,  Morris  Plains,  N  J).  TT  was  measured  with  Bovine  Topical 
Thrombin (Parke-Davis, Morris Plains, N  J). Citrated (3.8%) normal plasma was obtained 
from normal healthy laboratory personnel and used fresh. TT were also performed witb 
human fibrinogen (Kabi, Stokholm, Sweden) and purified human thrombin (courtesy of 
Dr. J. Fenton, Albany, NY). 
10-#1 aliquots ofporphyrin solutions were added to 1.0 ml plasma or fibrinogen solution 
(2.5 mg fibrinogen per milliliter phosphate buffer, pH 7.5) to make final concentrations 
of 0.0 t-0. t 0 mg/ml hematin. This range was chosen to approximate the range of plasma 
hematin concentrations seen in patients after intravenous hematin infusion. Unless other- 
wise indicated, anticoagulant activity (hematin-derived anticoagulant HDA) was assessed 
by  the  above  clotting  assays  performed  immediately after  the  addition  of porphyrin 
solutions to normal plasma or fibrinogen solutions.  Prolongation  of clotting times was 
quantitated by comparing the results with clotting times from plasma that had not been 
treated with hematin solutions, or to which buffer alone had been added. 
In Vitro Generation of  HDA (Aging of Hematin).  Hematin and other porphyrin solutions 
were  allowed  to  stand  (age)  at  4°C  exposed  to  ambient  light,  exposed  to  constant 
incandescent light (40 W lamp positioned 12 inches from the solution), or in total darkness. 
Hematin solutions were also aged in the presence of 2 mM mannitol, sorbitol, 2-ME, or 
butylated hydroxytoluene (BHT).  Anticoagulant activity of porphyrin solutions was as- 
sessed periodically with plasma clotting assays as above for over 6 wk of standing. 
Anticoagulant activity (aged hematin) generated in vitro was also tested in the presence 
of equimolar concentrations of fresh hematin, fresh and aged Sn-protoporphyrin IX, and 
fresh and aged protoporphyrin IX. Anticoagulant activity was also tested in the presence 
of varying concentrations of imidazole or desferrioxamine (Ciba Geigy). Anticoagulant 
activity was also tested in the presence of ferrioxamine, the iron chelate of desferrioxa- 
mine.  Ferrioxamine  was  produced  by  mixing  a  molar  excess  of ferric  chloride  with 
desferrioxamine, followed by alkalinization with  NaOH to pH 8.0  to remove unbound 
ferric iron. Desferrioxamine or ferrioxamine were added before or after HDA was added 
to plasma. 
TLC of Aged Hematin.  Hematin (aged 4 wk) solution containing HDA was spotted on 
a precoated silica  gel 60 plate (E.  Merck, Darmstadt, Federal Republic of Germany). A 
mixture of 2,6-1utidine and water (100 ml/60 ml) was placed in the bottom of chromato- 
graphic tank (20 ×  20  ×  8 cm), and three small beakers containing 7 N  NH4OH were 
placed in the tank. After saturation of the tank with NHs vapor, the TLC plate was placed 
upright  in  the  tank,  and ascending development was carried out  for 3  h.  Plates were 
divided into bands, scraped, and the resin was extracted with 1 N NaOH in 95% ethanol. 
Extracts were dried in a Savant Speed-Vac concentrator, redissolved in equal volumes of 
phosphosaline buffer (pH 7.4),  then  tested for HDA by adding aliquots to plasma and 
measuring APTTs. 
HPLC of  Aged Hematin.  Tetrabutylammonium hydroxide (TBAH) was purchased from 
Eastman-Kodak Co., Rochester, NY. Phosphate buffer was prepared using water purified 
to  18MSL by a  Milli-Q filtration system (Millipore Corp.,  Bedford,  MA).  All  solutions 
were deaerated by evacuation before use. HPLC conditions included a series 3B solvent 
distributor  (Perkin-Ehner  Corp.),  a  3u  C~s  column  (258-0160,  Perkin-Elmer  Corp.)  a 
septumless syringe  injector  (Rheodyne  7105),  and  LC  75  spectrophotometer (Perkin- 
Ehner Corp.). The mobile-phase solvent was methanol in  10 mM potassium phosphate 
buffer (pH 6.0) containing 5 mM TBAH. Methanol concentration was raised from 40 to 726  HEMATIN-DERIVED ANTIGOAGULANT 
99.9%  over  10  min with a  flow rate of 0.8  ml/min (13).  Hematin was detected  using 
absorption at 410 nm. Fractions were collected using a LKB Redi-Rac fraction collector. 
Data  were  analyzed  by a  3600  Chromatography  Data  Station  (Perkin-Elmer  Corp.). 
Fractions were dried as for TLC, reconstituted in equal volumes of phosphosaline buffer, 
and then tested for HDA by adding  10-ul aliquots from each fraction to  1.0  ml plasma, 
and measuring TTs. 
Dissociation of HDA from  Parent Hematin  Compound  in Plasma.  Aged  hematin  with 
HDA was added  to fresh normal citrated plasma (0.060  mg/ml) and incubated for 30 
rain. To assess total available HDA, the incubated plasma was mixed with an equal volume 
of untreated plasma, and TT was measured. This time was compared with an untreated 
plasma  TT.  HDA-treated  plasma  was  clotted  with  thrombin  (5  U/ml)  for  60  rain, 
centrifuged at 2,000  x  g for 30 min, and the serum was separated from the fibrin clot. 
The serum was then mixed with an equal volume of non-HDA-treated plasma, and TT 
was measured. This was compared with the TT obtained with serum fron nontreated 
plasma. Sera (treated and untreated) were also alkalinized with NaOH to pH 12, followed 
by addition of SDS (0.5% final concentration), and then neutralized with HCI. Total H DA 
activity was then assessed by measuring TT as for the dissolved clot (see below). This 
treatment did not significantly increase HDA releasable from serum samples. Plasma and 
serum hematin concentrations were assessed by measuring absorption at 405 or 610 nm 
and referring to a standard curve. 
The clot from the HDA-treated plasma was solubilized by alkalinization to pH 12 with 
NaOH and addition  of SDS to a  final concentration of 0.5%.  The solubilized clot was 
neutralized to pH 7.5  with  HCI. The volume of the solubilized clot was adjusted with 
phosphosaline buffer (pH 7.4) to equal the volume of the plasma from which the clot was 
obtained. The fibrin clot solution was then tested for HDA by adding to an equal volume 
of normal  plasma and  measuring  TT  as  above.  This  result  was  compared  with  TT 
measured with a clot solution from plasma which had not been treated with HDA. Neither 
treated nor untreated solubilized clots were clottable with thrombin. 
Generation of HDA In Vivo.  Male Sprague-Dawlye rats (Taconic Farms, Germantown, 
NY)  (250-300  g)  were  injected  in  the jugular  vein  with  freshly  prepared  hematin 
(preparation b) that had no HDA activity. Each rat was injected with 0.4 ml of a 10 mg/ml 
solution for a  dose of 12  mg/kg. Control rats were given 0.4  ml buffer. At each time 
point, three rats were anesthetized with ethyl ether and exsanguinated by aortic puncture. 
Citrated plasma was tested for PT, TT, APTT, and fibrinogen. Plasma fibrinogen was 
measured by the heat-precipitation method (14).  Serum and plasma hematin concentra- 
tions were assessed by the pyridine hemochromogen assay (12). 
Statistics.  Results are expressed as mean  and the range of observed values.  Where 
indicated, significance was tested by the student's t-test or by analysis of variance. 
Results 
Generation of  HDA In Vitro.  HDA was assessed at intervals in hematin solutions 
that  were  allowed  to  stand  at  4°C  for  over  6  wk  in  ambient  light,  direct 
incandescent  light,  or total darkness.  The results of generation of HDA by the 
aging of hematin solutions in ambient light are seen in Table I. The mean and 
range of values expressed as percent over control clotting times are shown  for 
aging in ambient light for both preparation a  (potassium phosphate buffer) and 
preparation  b (carbonate buffer).  Neither hematin preparation  shows any anti- 
coagulant activity (HDA) on  day zero.  However, by day 50,  both preparations 
have developed sufficient HDA activity to prolong clotting times by up to  188% 
(APTT) over control when added  to a  concentration  of 0.060  mg hematin per 
milliliter plasma. Prolongation of clotting times was more pronounced with TT 
and  APTT.  Fig.  1  shows  the  dose-dependent  prolongation  of clotting  times 
(APTT)  when  aged  or  fresh  hematin  is added  to  normal  plasma.  In  the  aged JONES 
TABLE  I 
Time Course of  HDA Generation from Hematin In Vitro 
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Age of 
solution (d) 
Control clotting times 
(s) 
HDA activity (percent above control clotting time, and actual clotting time [sl) 
Preparation a (phosphate  buffer)  Preparation b (carbonate buffer) 
PT  TT  APTT  PT  TT  APTT  PT  TT  APTT 
O  13.0  12.1  37.4  4.7 (13.6)  13.3 (13,8)  9.5 (40.9)  0.9 (12.8)  5.5 (12.9)  6.4 (39.8) 
4  13.3  13.1  35.4  0.9 (11,7)  7.0 (13.7)  5.5 (37.4)  0.9 (11.7)  5.2 (13.9)  6.4 (37.2) 
8  13.5  8.0  40.2  2.8(13.7)  17.7(11.1)  21.4(48.8)  0.9(12.5)  8.8(8.7)  14.1(4,5.9) 
12  13.4  9.5  39,4  2.6 (13.7)  14.3 (10.9)  18,2 (46,6)  0.9 (13.2)  10.6 (10.5)  13.4 (44.7) 
16  13,4  15.2  39.0  11.3 (14.9)  18.8 (18.1)  30.0 (50.7)  4,9 (14,1)  12.1 (17.0)  25.5 (48.9) 
22  12.0  11.8  33.8  22.0 (14.6)  116.8 (24.5)  71.6 (58.0)  10,5 (13,3)  53.9 (17.4)  71.7 (58.0) 
30  11.6  13.2  29.1  27.0 (•4.7)  140.6 (31.8)  136.9 (68.9)  18.3 (15.5)  116.5 (28.2)  113.3 (63.0) 
50  12.0  10.9  35.8  36.5(16.4)  154.8(27.8)  188.0(103.1)  34.4(16.1)  137.4(25.9)  183.0(101.3) 
Generation of H DA in vitro in two types of aging hematin preparations. Hematin was allowed to stand at 4 *C in ambient light, Anticoagulant 
activity was assessed at intervals by measuring  PT. TT, or APTT in I ml of fresh normal plasma immediately after addition of the equivalent 
of 0.060 mg bematin. Anticoagulant  activity (HDA) is expressed as the percent over a control clotting time, and the actual clotting times (s, 
in paremheses).  Control and HDA clotting times are the mean of three determinations.  HDA generation in these samples is representative 
of 10 such samples of aging hematin solutions. Anticoagulant activity developes slowly in these solutions. The effect on TT and APTT is 
greater than the effect on PT, 
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FIGURE  l.  Anticoagulant  activity  (HDA)  in  aged  hematin  solutions.  Aged  (50  d)  hematin 
added  to normal  citrated  plasma shows a  dose-dependent  prolongation  of APTT.  Activity is 
expressed  as  a  percentage  over  control  APTT  (untreated  plasma  APTT,  40.2  see).  Open 
circles  represent  actual  hematin  concentration  measured  in  the  aged  hematin  solution  by 
pyridine  hemochromogen.  Open  boxes  represent  hematin  concentration  predicted  from  the 
concentration  in solution when it was fresh. Closed circles show the activity in a  fresh (nonaged) 
solution. Each point shows the mean  and  range of determinations  on three plasma samples, 
preparation,  the amount of hematin  added  to plasma is expressed both as that 
measured by pyridine hemochromogen in the aged hematin solution, and as the 
amount predicted from the original hematin concentration when made up fi'esh. 
The  shift  to  the  left  of the  actual  amount  relative  to  the  predicted  amount 
indicates a fall in hematin concentration in the aged solution compared to when 
it was fresh. 
Acceleration  and Retardation  of HDA Generation.  Fig.  2  shows the  results  of 
aging hematin solutions in direct incandescent light or in total darkness. Fig. 2 a 728  HEMATIN-DERIVED  ANTICOAGULANT 
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FIGURE 2.  Effect of light and antioxidants on the generation of HDA in vitro. Hematin 
solutions were aged at 4 °C in direct incandescent light (40 W lamp at 12 inches)  or in complete 
darkness. Hematin  solutions were also aged  in  the presence of 2 mM  concentrations of 
mannitol (ll),  sorbitol (O), 2-mercaptoethanol (2-MCE) (&), or  BHT (x).  The solid line 
represents  hematin  allowed to age  without antioxidants ((3). (a)  Hematin  solutions aged 
exposed to constant direct light, and (b) hematin solutions  aged in the dark. The data represent 
the percent over a control APTT performed at each time point. Control APTT ranged from 
34.2-39.8 sec. Each data point shows the mean and range of determinations on three plasma 
samples. 
shows that HDA generation in direct light is greater than that seen with ambient 
light. Fig. 2 b shows that aging of hematin in total darkness generates lower levels 
of HDA  activity. While  the  presence or absence of light had  an  effect on  the 
generation  of anticoagulant  activity in  aging  hematin  solutions,  clotting times 
performed with added aged hematin were equally prolonged when performed 
in  the  light or  in  the  dark  with  a  mechanical  clot detection  device.  (data  not 
shown)  Thus,  HDA  activity  (prolongation  of  clotting  times)  found  in  aged 
hematin solutions was not affected whether the clotting assays were performed 
in the absence or presence of light. 
Fig.  2  also shows  the  results of HDA  generation  in  the presence of various 
antioxidant  compounds.  At  the concentrations  used,  none of the antioxidants 
had a  significant effect on clotting times when added to normal plasma without 
hematin solutions present (data not shown). When hematin solutions were aged 
in the presence of these antioxidants, significant retardation of the development 
of HDA was observed. Retardation of HDA generation by these compounds was 
seen  in  solutions  aged  both  in  the  light  (Fig.  2a)  or  in  the  dark  (Fig.  2b). 
Suppression of the generation of HDA was greatest in the solution aged in the 
light. 
Dissociation and Separation  of HDA from  Hematin in Aged  Hematin Solutions. 
HDA was dissociated from the parent hematin compound by TLC and HPLC. 
Fig. 3 shows that the major band of HDA activity (prolongation of APTT) elutes 
at an appreciably lower Rf than hematin in TLC. It is notable that the band with 
the  highest activity is  not associated with pigment.  Fig.  4  shows  the results  of 
HPLC of fresh and aged hematin solutions. The elution pattern of absorption at 
410  nm  of fresh  hematin  solution  clearly differs from that  of aged  hematin. JONES  729 
FIGURE 3.  TLC of aged hematin solution. Aged hematin (60 d) was eluted on silica gel-60 
with 2,6-1utidine and water in a tank saturated with NHs vapor. The plates were divided into 
bands that were scraped, and the resin was extracted for HDA. HDA was tested by adding 
aliquots from concentrated extracts to plasma and measuring APTTs. The parent compound 
(hematin) elutes at Rf 0.5. The major band of HDA elutes at a lower Rf, and is not associated 
with pigment. Similar results were seen with TT determinations. 
o  -'-'J 
;f 
° 
O  c 
~*ooE  /  ',, 
o 2oo~  .~  j ~.  ',, 
0  2  4  6  8  iO  12  14  IS  18 
Elution Time (minutes) 
FIC,  URE  4.  HPLC of fresh and aged hematin solutions. Hematin solutions were chromato- 
grammed on reverse-phase (Cls) columns. HDA was tested by adding aliquots from concen- 
trated fractions to plasma and measuring TTs. Closed circles (0) represent fresh hematin and 
open circles (O) represent aged hematin (50 d). HDA elutes significantly after the major band 
associated with  fresh  hematin  solution.  HDA  also  elutes  in  fractions not  associated with 
absorption at 410 nm. 
HDA  activity  (prolongation  of  TT)  elutes  after  the  parent  hematin  peak  in 
fractions with low absorption at 410  nm. 
Dissociation and Separation  of HDA from Hematin in Plasma.  Normal  citrated 
plasma with added aged hematin solution (0.06 mg/ml) was clotted with thrombin 
(5  U/mi)  for  60  min  at  37°C,  then  centrifuged,  and  the serum  and  fibrin clot 
were  separated.  HDA  was  tested  in  both  the  serum  and  dissolved  fibrin  clot 
fractions  by  adding  the  fractions  to  an  equal  volume  of  normal  plasma  and 
measuring  TTs.  The  results  are  seen  in  Table  II.  When  compared  to  the 
corresponding  control serum  or dissolved clot fraction  (not treated  with  HDA) 
the dissolved clot fraction prolonged the thrombin  time considerably longer than 730  HEMATlN-DERIVED ANTICOAGULANT 
TABLE II 
Segregation of Hematin and HDA into Serum or Dissolved Clot 
Fractions of Plasma 
Hematin  Hematin  Plasma  Control  HDA  concentra-  added 
fraction  TT (s)  (range)  tion (mg/ml)  (%) 
Whole  10.5  80.5 (64-90)  0.064  100 
Dissolved clot  15.3  97.0 (78-109)  0.012  19.4 
Serum  12.6  27.6 (18-38)  0.050  78.3 
Segregation of HDA into the  dissolved clot fraction of whole plasma. 
Aged bematin solution (0.064 mg/ml) was added to normal plasma and 
incubated for 30 min at 37 °C. The plasma was then clotted with thrombin 
(5 U/ml) for 60 min, and the clot was separated from the serum. The clot 
and serum were treated with NaOH and SDS, and HDA activity deter- 
mined by mixing the fractions with an equal volume of normal plasma. 
TT of these mixtures were measured and the results were compared with 
TT measured for the corresponding fraction (whole plasma, dissolved clot 
fraction, or serum fraction) prepared in the same fashion from untreated 
plasma (no added hematin solution). HDA activity is expressed as percent- 
age  above the  corresponding  control  thrombin  time. Treated  whole 
plasma prolonged the thrombin time by 80.5% over the control plasma 
value. The dissolved plasma clot fraction prolonged the thrombin time by 
97%, while the serum fraction prolonged the thrombin time by 27.6% 
over the corresponding control value. Hematin measured by absorption 
at 610 nm segregated largely (78.3%) into the serum fraction. The results 
represent the means of 10 experiments. 
the serum fraction (97 vs. 27.6%  over control). This suggests that HDA prefer- 
entially  segregated  into  the  clot  fraction.  On  the  other  hand,  hematin,  as 
measured by absorption at 610 nm, was largely distributed in the serum fraction. 
Inhibitors of HDA Prolongation of Clotting Times.  Prolongation of clotting times 
(HDA) found in aged hematin solutions was tested in plasma in the presence of 
fresh  (nonaged)  hematin  solution,  fresh  or  aged  Sn-protoporphyrin  IX  (Sn- 
heine)  or  fresh  or  aged  protoporphyrin  IX.  The  results  of the  clotting times 
expressed  as  percent  over control  from these  experiments  are  seen  in  Fig.  5. 
Neither fresh hematin nor fresh Sn-protoporphyrin IX alone had any significant 
effect, whereas aged Sn-protoporphyrin IX alone showed a  small prolongation 
of thrombin  times.  When  fresh hematin  or fresh  Sn-protoporphyrin IX were 
added in equimolar amounts with aged hematin, there was a significant reduction 
in HDA activity as measured by plasma thrombin times. Aged Sn-protoporphyrin 
IX added to plasma with aged hematin showed a  small augmentation of HDA. 
Neither fresh nor aged protoporphyrin IX had an effect on plasma clotting times 
when added alone or with equimolar concentrations of aged hematin (data not 
shown). 
HDA was also tested  in  the presence of varying concentrations of imidazole. 
Dose-dependent reduction  of HDA was seen  when plasma  clotting times were 
measured with the addition of imidazole (0-50 mM, final concentration) before 
adding  HDA (data  not  shown).  Imidazole was  also  added  to  either  a  purified 
fibrinogen  or  a  purified  thrombin  solution  5  rain  before  addition  of  HDA. 
Clotting times were measured by adding treated thrombin to untreated fibrino- 
gen or untreated  thrombin to treated  fibrinogen.  In a  purified fibrinogen and 8 
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FIGURE 5.  Inhibitory effect of fresh heine and tin-heine on  HDA.  Hematin aged  60 d  was 
added  to plasma  at  0.06  mg/ml  and  tested  for  HDA  activity in  the presence  of equimolar 
amounts of fresh hematin,  fresh tin-heine or aged (60 d) tin-heme solutions.  These solutions 
were also tested for anticoagulant  activity without added  aged  hematin  (HDA).  The results 
are expressed as the percent over a control TT (7.6 see). The data shows the mean and range 
for  TT  determinations  performed  on  three  samples.  Equimolar  concentrations  of  fresh 
hematin  or  tin-heine  significantly  reduce  HDA.  Aged  tin-heine  solution  alone  produces  a 
significant  prolongation  of  thrombin  times.  Addition  of aged  tin-heme  to  aged  hematin 
augments HDA. 
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FIGURE 6.  Inhibition of HDA by imidazole. Imidazole was added to fibrinogen or thrombin 
solutions before addition  of HDA (hematin  aged  50 d, 0.06  mg/ml). TT were measured  by 
adding  treated  thrombin  to  untreated  fibrinogen  (a)  or by adding  untreated  thrombin  to 
treated fibrinogen solution (b). The results shown are the mean and range of the percent over 
a control TT  (10.5 sec) of three experiments.  Imidazole added to achieve concentrations of 
10-50 mM produced a dose-dependent inhibition of HDA. Addition of ferric citrate (50 raM) 
to the treated solutions reverses the inhibition of HDA produced by imidazole. 
thrombin system, TT prolongation produced by HDA was inhibited if imidazole 
was  added  first  either  to  the  fibrinogen  or  the  thrombin  (Fig.  6).  Control 
experiments showed no effects on TT when imidazole was added to either the 
thrombin or fibrinogen solutions in the absence of HDA. 
Since iron chelation  by imidazole may participate in the inhibition of HDA, 
these experiments were also performed in the presence of 50 mM ferric citrate. 732  HEMAT1N-DERIVED  ANTICOAGULANT 
Ferric  citrate  alone  (no  imidazole) produced  no  additional  prolongation  of 
clotting times over that produced by HDA. Fig. 6 shows that ferric iron as ferric 
citrate reverses the inhibition of HDA produced by imidazole. 
To further examine the role of iron in the mechanism, HDA was also tested 
before (blockade) and after (reversal) the addition of the specific iron chelator, 
desferrioxamine. Fig.  7 shows the dose-dependent (0-0.3  mg/ml) blockade of 
anticoagulant activity produced by desferrioxamine when added before HDA in 
a  purified fibrinogen/thrombin time experiment. This figure also  shows  that 
ferrioxamine, the  iron  chelate of desferrioxamine, produced no blockade of 
HDA activity.  Reversal of HDA in plasma was attempted by adding desferriox- 
amine after the addition of HDA. Desferrioxamine alone added to plasma did 
not shorten the thrombin time. Table III shows a dose-dependent reversal of 
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FIGURE 7.  Dose-dependent blockade of HDA by desferrioxamine. TT were measured with 
human fibrinogen (2.5 mg/ml) and thrombin. 5 min before addition of HDA, desferrioxamine 
or ferrioxamine was added to the fibrinogen solution. HDA (bematin aged 60 d) was added 
at a concentration of 0.06 mg]ml, and then TT was measured 2 rain later. The data represent 
the mean and range of percent over control  TT  (6.8  sec) observed for four experimental 
samples. Neither desferrioxamine (Des)  nor ferrioxamine (Fer)  show an effect on the clotting 
time when added alone (no HDA) to fibrinogen. In combination with HDA, desferrioxamine 
shows a dose-dependent blockade of anticoagulant activity, whereas the iron chelate, ferriox- 
amine, shows no inhibition of HDA. 
TABLE  III 
Reversal and Blockade of HDA Activity by Desferrioxamine in Plasma 
Desferrioxamine 
added to plasma 
(mg/ml) 
Remaining HDA activity (prolongation of ATT) 
Reversal  Blockade 
Percent  TT (s)  Percent  TT (s) 
0.10  80  31.4  75  30.3 
0.30  75  30.4  64  27.9 
0.50  62  27.5  54  25.8 
Reversal and blockade of HDA by desferrioxamine in plasma. Desferriox- 
amine (0-0.5 mg/ml) was added to citrated plasma 5 min after (reversal) 
or 5 min before (blockade) the addition of HDA from hematin aged 50 d 
(0,06 mg]ml). Control TT was 14.5 s. Addition of aged hematin prolonged 
TT to 35,7 s. Desferrioxamine alone produced a small (4%) prolongation 
of the thrombin time at 0.5 mg/ml.  Data is expressed as percent of the 
remaining HDA activity (prolongation of 21.2 sec over control,  100%). 
Actual thrombin times are also shown. The results shown are the means 
of thrombin times performed on four separate samples. Desferrioxamine 
reverses as well as blocks HDA activity. JONES  733 
HDA activity in plasma when desferrioxamine (0-0.5 mg/ml) was added 5 min 
after the addition of HDA. Dose-dependent reversal was also shown by adding 
desferrioxamine up to 30  rain after addition of HDA (data not shown). These 
results  indicate  that  the  mechanism of action  of HDA  does  not  involve  an 
irreversible or destructive effect on coagulation proteins. 
Generation  of HDA  In  Vivo.  Fresh  hematin  solution  was  prepared  as  for 
infusion into a  patient (preparation b).  This preparation had no HDA activity 
(prolongation of clotting times) when tested within  1 h  after preparation and 
injection. Rats were given intravenous injections of this hematin preparation (12 
mg/kg).  Control  rats  (time zero)  were given  an  equal  volume of buffer and 
showed no anticoagulant effect. There was no effect on plasma PT by hematin 
infusion. Fig. 8 shows the results of plasma hematin, fibrinogen, TT, and APTT 
in  these experiments. There was a  delay between the rise  in plasma hematin 
levels (i rain) and the appearance of anticoagulant activity (3 min). Furthermore, 
prolongation of the APTT and TT persisted long after the fall in plasma hematin 
concentration. These results show a  temporal dissociation between hematin in 
the plasma and anticoagulant activity produced by infusion of fresh hematin, 
and suggests that a  modification of hematin leads to HDA in vivo. No change 
was seen in plasma fibrinogen measured by heat precipitation. This is consistent 
with  previous  observations  (11)  in  patients  with  AlP.  Fig.  8  also  shows  that 
desferrioxamine (0.5  mg/ml) added  to  these citrated plasma samples reverses 
anticoagulant activity produced by HDA in vivo. Reversibility with desferriox- 
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FIGURE 8.  Generation of HDA in vivo. Fresh hematin (no HDA) was injected intravenously 
by jugular vein into rats and samples were drawn for plasma hematin (pyridine hemochromo- 
gen), clotting times and plasma fibrinogen. Plasma fibrinogen was measured by heat precipi- 
tation. Each histogram shows the mean and range of determinations from three rats sacrificed 
at each time point. The clotting time data are presented as the percent over control clotting 
times (APTT, 17.3 sec, TT, 14.0 sec). Anticoagulant activity (prolonged APTT i[striped bars] 
and  TT  [open  bars  below APTT]) appears  3  min after bematin  injection, whereas plasma 
hematin (solid bars) levels are elevated after  1 rain.  Plasma fibrinogen levels (~-------O) show 
no change measured by heat precipitation (analysis  of variance). Clotting times (open bars) are 
prolonged considerably after the  fall in  plasma  hematin  concentration.  There  is a  greater 
effect on  APTT compared to TT, There is statistically significant prolongation of clotting 
times (p <  0.05, student's t-test)  for all points after hematin infusion except for 1 min and 6 h 
(TT). Shaded areas within the clotting time histograms represent the mean clotting time after 
desferrioxamine (0.5 mg/ml) was added to the plasma.  Desferrioxamine reverses the prolon- 
gation of clotting times produced  by in vivo generated  HDA. This effect is more dramatic 
with APTT. 734  HEMATIN-DERIVED  ANTICOAGULANT 
amine suggests that HDA activity seen in vivo and HDA produced in vitro in 
aging hematin solutions, have similar mechanisms. 
Discussion 
Recent clinical trials have shown that infusions of hematin (ferriprotoporphyrin 
IX hydroxide) are effective in preventing or abating the painful crises associated 
with AIP. (6-8) Preparations of hematin have now become commercially avail- 
able, and it is expected that the use of this compound for therapy in porphyria 
patients will become more widespread. With the limited use thus far, few adverse 
reactions have been reported after infusions of hematin. Chemical phlebitis and 
reversible acute renal insufficiency have been rarely reported (15,  16).  More 
recently however, hematin  infusion  has  been  reported  to  be  associated with 
profound effects on coagulation tests. (9, 10) Glueck et al. (11) reported elevation 
of the standard clinical clotting assays, elevation of fibrin degradation products, 
decreases in the levels of clotting factors, including fibrinogen, and thrombocy- 
topenia. These observations suggested a picture of intravascular coagulation with 
consumption of clotting factors.  On the other hand, when these investigators 
measured fibrinogen concentration by heat precipitation, no decrease was found. 
This suggests that the prolongation of clotting times produced by hematin is due 
to interference with coagulation factor mechanisms rather than consumption of 
clotting factors. The present study indicates that prolongation of clotting times 
produced by hematin is due to a degradation product or derivative of hematin 
(HDA) that reversibly inhibits the action of one or more coagulation factors. 
HDA was generated in vitro by allowing solutions to stand (age) at 4°C. The 
generation was time dependent on and accelerated by light. The acceleration by 
light suggests that an oxidation or free radical-mediated alteration of hematin 
is responsible for the generation of HDA.  Retardation of HDA generation by 
mannitol, sorbitol, 2-ME, or BHT supports this idea, since these compounds are 
antioxidants and free radical scavengers. Acceleration by light also suggests that 
generation of HDA in vitro is promoted by a photodynamic effect. However, a 
photodynamic effect is  not responsible  for the anticoagulant action of HDA, 
because clotting times measured in the dark are equally prolonged compared to 
those measured in  the light.  This distinguishes HDA from the photodynamic 
destructive effects on clotting proteins and the prolongation of clotting times 
described for hematoporphyrin (17,  18). 
Dissociation of HDA  from the parent compound hematin was also demon- 
strated when plasma containing HDA was clotted with thrombin. Although the 
interpretation  of such  experiments  may be  complicated  by  the  presence  of 
procoagulants and/or inhibitors generated by the clotting process, these factors 
were controlled for by comparing the experimental clotting times with the results 
produced by  the appropriate  untreated  clot  or  serum fractions.  Using these 
controls, the results show that HDA activity largely segregated into the fibrin 
clot fraction, whereas hematin remains largely in the serum. This suggests that 
HDA binds to clottable protein or fibrinogen. 
TLC and HPLC experiments also showed clear separation of HDA from the 
parent hematin compound when aged hematin solutions were chromatographed. 
Besides showing a distinction between hematin and HDA, the results of the TLC JONES  735 
and HPLC experiments also suggest that HDA may be due to a single derivative 
or degradation  product  of the  in  vitro hematin  aging process.  Unfortunately, 
little is known about nonenzymatic degradation of heine or other porphyrins in 
vitro. In a study of methemalbumin, Rosenfeld and Surgenor found that hematin 
was transformed to a product that did not have the albumin-binding character- 
istics of heme  (19).  This  unidentified  product  was formed  when  hematin  was 
allowed to stand for several hours under conditions similar to the aging process 
described above. Under these conditions,  it is possible that  hematin  undergoes 
attack by oxygen or hydroxyl radicals. Some of these reactions may take place at 
the a-methene carbon,  leading to products similar to those generated  by enzy- 
matic degradation (20). Hematin in aqueous solution is also known (21) to form 
soluble and  insoluble polymers or aggregates.  However,  these polymers seem 
unlikely candidates  for  HDA, since the  TLC and  HPLC experiments showed 
HDA eluting in fractions not associated with pigment or absorption at 410 nm. 
Further evidence that HDA is a derivative of hematin rather than the parent 
compound is provided by the experiments showing inhibition by freshly prepared 
solutions of hematin  and  Sn-protoporphyrin.  It is apparent  that  a  breakdown 
product will bear some structural similarity to the parent compound. Therefore, 
the  observed  inhibition  of anticoagulant  activity  suggests  that  nondegraded 
metalloporphyrins  interact  with or block specific sites on  coagulation  proteins 
that must be available for HDA activity. Also, neither fresh nor aged protopor- 
phyrin  IX showed inhibition  of HDA when added in equimolar amounts.  The 
lack of anticoagulant activity or inhibition of anticoagulant activity produced by 
aged or fresh protoporphyrin  IX indicates  that a  metal must be present in the 
porphyrin ring to cause breakdown to HDA or inhibition of HDA by the fresh 
porphyrin. 
Imidazole  showed  a  dose-dependent  inhibition  of HDA.  More  specifically, 
imidazole prevents or retards the inactivation of thrombin or fibrinogen, and it 
appears  that  this  effect is  more  pronounced  with  fibrinogen  (Fig.  6).  In  the 
hemoglobin molecule, heme binds to globin partially through  an interaction  of 
the iron of heine and a histidine residue (imidazole) of globin (22, 23). Inhibition 
of HDA  by  imidazole,  and  the  observed  reversal  of  this  inhibition  by  iron 
suggests that iron or a  metal atom may play an important  role in the action of 
HDA.  This  result  also  suggests  the  possibility  that  HDA  may  interact  with 
histidine residues of clotting proteins to produce prolongation of clotting times. 
Blockade and  reversal  of HDA by desferrioxamine  is further  evidence that 
iron is involved in the mechanism of HDA activity. Failure of ferrioxamine (the 
iron  chelate  of desferrioxamine)  to  inhibit  HDA  shows that  the  iron-binding 
capacity of desferrioxamine is necessary for the inhibition. Reversal of the activity 
indicates that the interaction of HDA with coagulation proteins is not destructive, 
and  that  the  structural  integrity  of the  coagulation  proteins  affected is  main- 
tained.  The apparent  role of iron  in the mechanism  of HDA and the observed 
reversibility of HDA activity are notable in light of the coagulation defect seen 
in acute iron toxicity. A recent report by Rosenmund et al. documents that ferric 
iron autoxidized from ferrous sulfate causes a functional impairment ofthrombin 
and other coagulation proteases which prolongs coagulation times (24). Similarly 
to HDA, this functional  impairment  was also reversible with chelation of iron. 736  HEMATIN-DERIVED  ANTICOAGULANT 
The lowest level of free iron used in their study was 8-80-fold higher than those 
that are possible from the hematin used herein. It is therefore unlikely that free 
iron from degraded hematin is responsible for HDA activity. 
In the experiments in rats, when fresh hematin solution containing no HDA 
was  injected as  an  intravenous  bolus,  anticoagulant activity appeared  in  the 
plasma after the rise in plasma hematin concentration. Furthermore, anticoagu- 
lant activity persisted after the fall in plasma hematin. This indicates a temporal 
dissociation  of prolongation  of clotting time activity (HDA)  from the parent 
hematin compound in vivo. Although the time sequence of prolonged clotting 
times after hematin infusion has not been precisely defined, the results in rats 
reported here are consistent with published information from human studies. 
The very rapid time course of generation of HDA in vivo, suggests a metabolic 
conversion of hematin that leads to HDA activity rather than the slow degrada- 
tion or derivatization seen in vitro.  Bilirubin and other bile pigments are the 
major metabolic products recovered when heme is administered intravenously 
to rats (25).  These pigments are produced by the microsomal heme-oxygenase 
system, which is thought to play the dominant role in physiologic heme catabolism 
(26). Recently, (27, 28), however, NADPH-cytochrome c reductase has also been 
found  to  degrade  heme in  a  less  specific manner to  a  mixture of dipyrrolic 
propentdyopents. This system is distinct from the heme-oxygenase catabolism of 
heme, and bile pigments are not intermediates in this pathway. Propentdyopents 
have been found in gallstones and urine, and this mode of heme catabolism has 
been suggested (29)  to be operative at low levels in  normal  metabolic states. 
Therefore, these products as well as the bile pigments must be considered as 
candidates for HDA. 
Although the structural identity of HDA was not identified by this study, in 
vitro (TLC and HPLC) experiments indicate that HDA is a single derivative of 
hematin. Furthermore, it is also probable that this compound contains iron, or 
that iron is necessary for the anticoagulant action. Reversal of HDA activity in 
plasma from the hematin-treated rats by desferrioxamine suggests that a common 
mechanism and derivative is responsible for HDA activity produced in vitro and 
in vivo. The mechanism for the anticoagulant action is also likely related to a 
reversible binding of HDA to clotting proteins.  In a  recent study of hematin 
effects on  hemostasis, Green and associates (30)  showed that the parent com- 
pound binds to fibrinogen and albumin  in  vitro.  Miiller-Eberhard and others 
(31, 32) have shown that, in vivo, hematin (heine) is bound most specifically to 
hemopexin and albumin. This binding and subsequent uptake by the liver is the 
major pathway for clearance of hematin from the plasma. Since HDA segregates 
largely  into  the  clot  fraction  of whole  plasma,  it  appears  that  HDA  binds 
preferentially to  fibrinogen  and/or  other  clotting  proteins,  with  a  resultant 
anticoagulant effect. 
The results outlined above have obvious clinical implications. To avoid infusion 
of hematin that has anticoagulant activity, one should  use material as freshly 
prepared from heroin (ferriprotoporphyrin IX  chloride) as possible.  We  have 
recently  examined  the  commercially available  product  Panhematin  (Abbott 
Laboratories), which is a lyophilized preparation of hematin. This product, when 
freshly dissolved with sterile H20 as for infusion, showed prolongation of plasma JONES  737 
clotting times in vitro (40% increase in APTT at a plasma concentration of 0.078 
mg/ml).  Furthermore,  the  anticoagulant  activity detected  in  this  preparation 
eluted  in  an  identical  fraction  to  HDA in  the  HPLC system described above. 
This indicates that stored hematin may degrade to HDA before or after lyophi- 
lization,  and  that  only products  freshly  prepared  from  heroin  will  be  free  of 
HDA.  On  the  other  hand,  the  experiment  in  rats  suggests  that  even  freshly 
prepared  hematin  may be metabolically converted to produce an anticoagulant 
(HDA?) in  vivo.  Thus,  this  potential  toxicity of hematin  infusion  may not  be 
avoidable. Finally, if it is confirmed that the appearance of HDA in vivo is due 
to metabolic conversion of hematin,  it is possible that endogenous heme or other 
porphyrins are converted to HDA. Confirmation  that these molecules and their 
effects on  hemostasis exist  in  normal  or  disease states awaits purification  and 
structural identification of HDA from in vitro and in vivo sources. The fact that 
the  anticoagulant  effect  of hematin  (heine)  derivatives  may  be  inhibited  by 
pharmacologic  agents,  such  as  desferrioxamine  or  the  synthetic  analogue  of 
heme,  Sn-protoporphyrin,  raises  the  possibility  that  such  agents  may also  be 
useful  to  suppress  HDA  in  clinical  circumstances  where  HDA  may  lead  to 
increased risk of hemorrhage. 
Summary 
Prolongation  of clotting times produced by hematin  was investigated both in 
vitro and in vivo. Hematin-derived anticoagulant (HDA) was found to be due to 
a  degradative product or derivative of hematin,  and was generated  in vitro in 
standing (aging) aqueous solutions of the parent compound. Generation of HDA 
in  vitro  was  inhibited  by antioxidants.  The  anticoagulant  effect of HDA  was 
inhibited  by freshly prepared  hematin,  fresh Sn-protoporphyrin,  imidazole,  or 
the  iron  chelator  desferrioxamine.  Ferrioxamine  did  not  inhibit  HDA,  and 
inhibition by imidazole was reversed with ferric citrate, suggesting a role for iron 
in the mechanism  of HDA activity. HDA activity was dissociated from hematin 
in  plasma  by clotting  with  thrombin.  HDA  segregated  into  the  clot  fraction, 
whereas hematin  remained  largely in the serum fraction, suggesting that  HDA 
may preferentially bind to fibrinogen. TLC and HPLC showed a single peak of 
HDA activity that  was not associated with  the parent  compound.  Evidence for 
HDA generation in vivo was found when rats were injected with fresh (no HDA) 
hematin.  Prolongation of clotting times appeared after hematin appeared in the 
plasma, and anticoagulant  activity persisted after a  fail in plasma hematin  con- 
centration. Thus, there was a temporal dissociation between hematin and HDA, 
suggesting that a  modification of hematin  must occur in vivo before an antico- 
agulant  effect  is  produced.  Generation  of HDA  in  vitro  has  implications  for 
hematin  preparation  and administration.  Generation  of HDA in  vivo suggests 
that similar modifications of endogenous heine or other porphyrins may occur 
to produce HDA under physiologic or pathophysiologic conditions. 
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